China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu
China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu Detail:
Manufacturer with High Purity and Stable Quality
Chemical Name: Levodopa
Synonyms: L-DOPA; 3-(3,4-Dihydroxyphenyl)-L-alanine
CAS: 59-92-7
Anti-Parkinson’s Disease
API USP/BP/EP/IP Standard, High Quality, Commercial Production
Chemical Name | Levodopa |
Synonyms | L-DOPA; 3-(3,4-Dihydroxyphenyl)-L-alanine |
CAS Number | 59-92-7 |
CAT Number | RF-API55 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C9H11NO4 |
Molecular Weight | 197.19 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White or Milk White Crystalline Powder |
Identification | Must Positive |
Particle Size | 100% Pass Through 80 |
Related Substances | |
L-Tyrosina | ≤0.10% |
Levodopareted Compound | ≤0.10% |
3-Methoxytyrosine | ≤0.50% |
Total Impurities | ≤1.0% |
Unknow Impurities | ≤0.10% |
PH | 4.5~7.0 |
Absorptivity | 137~147 |
Optical Rotation | -1.27°~-1.34° |
Heavy Metals | ≤10ppm |
Loss on Drying | ≤1.0% |
Melting Point | 249.5~252.5℃ |
Heavy Metals | ≤20ppm |
Sulphated Ash | ≤0.10% |
Assay | 99.0%~100.5% |
Test Standard | USP/BP/EP/IP Standard |
Usage | Active Pharmaceutical Ingredient (API); Anti-Parkinson’s Disease |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Levodopa (L-DOPA) used in the treatment of Parkinson’s disease. Levodopa (L-DOPA), the most reliable and effective drug used in the treatment of parkinsonism, can be considered a form of replacement therapy. Levodopa is the biochemical precursor of dopamine. It is used to elevate dopamine levels in the neostriatum of parkinsonian patients. Dopamine itself does not cross the blood-brain barrier and therefore has no CNS effects. However, levodopa, as an amino acid, is transported into the brain by amino acid transport systems, where it is converted to dopamine by the enzyme L-aromatic amino acid decarboxylase.
If levodopa is administered alone, it is extensively metabolized by L-aromatic amino acid decarboxylase in the liver, kidney, and gastrointestinal tract. To prevent this peripheral metabolism, levodopa is coadministered with carbidopa (Sinemet), a peripheral decarboxylase inhibitor. The combination of levodopa with carbidopa lowers the necessary dose of levodopa and reduces peripheral side effects associated with its administration. Levodopa is widely used for treatment of all types of parkinsonism except those associated with antipsychotic drug therapy. However, as parkinsonism progresses, the duration of benefit from each dose of levodopa may shorten (wearing-off effect). Patients can also develop sudden, unpredictable fluctuations between mobility and immobility (on-off effect). In a matter of minutes, a patient enjoying normal or nearly normal mobility may suddenly develop a severe degree of parkinsonism. These symptoms are likely due to the progression of the disease and the loss of striatal dopamine nerve terminals.
Product detail pictures:
![China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu detail pictures](https://www.ruifuchemical.com/uploads/L-DOPA-Levodopa-CAS-59-92-7-API.jpg)
Related Product Guide:
China OEM Cinchonidine - L-DOPA Levodopa CAS 59-92-7 API USP BP EP Standard Anti-Parkinson’s Disease High Purity – Ruifu , The product will supply to all over the world, such as: , , ,
![5 Stars](https://www.ruifuchemical.com/admin/img/star-icon.png)
![5 Stars](https://www.ruifuchemical.com/admin/img/star-icon.png)